- Reaction score
- 1,701
The consumer genome sequencing company 23andMe is a sinking ship – and its CEO is conducting the orchestra.
As Wired reports, 23andMe CEO Anne Wojcicki was chipper on a February 7 earnings call despite the company's abysmal revenue report that led to its stock being devalued to below 75 cents per share, down a whopping 93 percent from the $16.04 when it first went public.
"We are an unusual company," Wojcicki said, per Wired, during the investor call.
That response very much undersells the circumstances that may lead to 23andMe spinning off its consumer DNA testing and therapeutics wings into separate entities, like so many unraveled strands of double helixes.
As Wired reports, 23andMe CEO Anne Wojcicki was chipper on a February 7 earnings call despite the company's abysmal revenue report that led to its stock being devalued to below 75 cents per share, down a whopping 93 percent from the $16.04 when it first went public.
"We are an unusual company," Wojcicki said, per Wired, during the investor call.
That response very much undersells the circumstances that may lead to 23andMe spinning off its consumer DNA testing and therapeutics wings into separate entities, like so many unraveled strands of double helixes.
23andMe CEO Says Company Is Doing Fine Despite Losing 93% of Stock Value
The consumer genome sequencing company 23andMe is a sinking ship – and their CEO is on the deck, playing the violin.
futurism.com